These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 28449482)

  • 1. Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).
    Oskan F; Dzierma Y; Wagenpfeil S; Rübe C; Fleckenstein J
    J Thorac Dis; 2017 Mar; 9(3):742-756. PubMed ID: 28449482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
    He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
    Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcomes of Stereotactic Ablative Body Radiotherapy on Extra-cranial Oligometastatic and Oligoprogressive Breast Cancer: Mature Results from a Single Institution Experience.
    Armstrong S; Makris A; Belessiotis-Richards K; Abdul-Latif M; Ostler P; Shah N; Miles D; Tsang YM
    Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):362-369. PubMed ID: 38575431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of single fraction stereotactic ablative radiotherapy for lung metastases.
    Filippi AR; Badellino S; Guarneri A; Levis M; Botticella A; Mantovani C; Ragona R; Racca P; Buffoni L; Novello S; Ricardi U
    Technol Cancer Res Treat; 2014 Feb; 13(1):37-45. PubMed ID: 23819496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can dosimetry affect local control and survival in patients with early-stage lung cancer treated with Stereotactic Ablative Radiotherapy (SABR)? An analysis of the UK's largest cohort of lung SABR patients.
    Saha A; Beasley M; Hatton N; Dickinson P; Franks K; Clarke K; Jain P; Teo M; Murray P; Lilley J
    Acta Oncol; 2021 Apr; 60(4):505-512. PubMed ID: 33491521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of stereotactic ablative body radiotherapy on oligometastases from colorectal cancer: early results of a single institution service evaluation.
    Duong J; Stewart-Lord A; Nariyangadu P; Harrison M; Tsang YM
    BJR Open; 2022; 4(1):20210071. PubMed ID: 36105422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
    Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
    Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
    Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    Franzese C; Vernier V; Franceschini D; Comito T; Navarria P; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Marini B; Galdieri C; Mancosu P; Tomatis S; Scorsetti M
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10495-10503. PubMed ID: 37280407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients.
    Upadhyay R; Klamer B; Matsui J; Chakravarthy VB; Scharschmidt T; Yeager N; Setty BA; Cripe TP; Roberts RD; Aldrink JH; Singh R; Raval RR; Palmer JD; Baliga S
    Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control.
    Patel PR; Kirkpatrick J; Salama JK; Nelson J; Broadwater G; Allen K; Clough R; Yin FF; Wang Z; Chang Z; Kelsey C; Ghafoori AP
    J Radiosurg SBRT; 2014; 3(2):123-129. PubMed ID: 29296393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up.
    Agolli L; Bracci S; Nicosia L; Valeriani M; De Sanctis V; Osti MF
    Clin Colorectal Cancer; 2017 Mar; 16(1):58-64. PubMed ID: 27522627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
    Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
    Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
    BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
    Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
    Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
    Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved local control following dose-escalated stereotactic ablative radiation therapy (SABR) for metastatic sarcomas: An international multi-institutional experience.
    Singh R; Konrad A; Roubil JG; Jenkins J; Davis J; Austin Vargo J; Gogineni E; Sharma S
    Radiother Oncol; 2024 Jan; 190():110020. PubMed ID: 38007042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.